These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Evaluation of a short-term topical interferon α-2b treatment for histologically proven melanoma and primary acquired melanosis with atypia. Garip A, Schaumberger MM, Wolf A, Herold TR, Miller CV, Klingenstein A, Schebitz-Walter K, Hintschich CR. Orbit; 2016 Apr; 35(1):29-34. PubMed ID: 26636727 [Abstract] [Full Text] [Related]
3. Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Frucht-Pery J, Pe'er J. Arch Ophthalmol; 1996 Oct; 114(10):1261-4. PubMed ID: 8859090 [Abstract] [Full Text] [Related]
11. [Two cases of conjunctival malignant melanoma treated with topical interferon alpha-2b drop as an adjuvant therapy]. Kase S, Ishijima K, Noda M, Ishida S. Nippon Ganka Gakkai Zasshi; 2011 Nov; 115(11):1043-7. PubMed ID: 22171510 [Abstract] [Full Text] [Related]
12. Interferon alfa-2b in the management of recurrent conjunctival papillomatosis. Singh M, Gautam N, Gupta A, Kaur M. Indian J Ophthalmol; 2016 Oct; 64(10):778-780. PubMed ID: 27905345 [Abstract] [Full Text] [Related]
13. Use of interferon alpha 2b to manage conjunctival primary acquired melanosis and conjunctival melanoma. Cid-Bertomeu P, Huerva V. Surv Ophthalmol; 2022 Oct; 67(5):1391-1404. PubMed ID: 35278438 [Abstract] [Full Text] [Related]
16. The treatment of primary acquired melanosis (PAM) with atypia by topical Mitomycin C. Pe'er J, Frucht-Pery J. Am J Ophthalmol; 2005 Feb; 139(2):229-34. PubMed ID: 15733981 [Abstract] [Full Text] [Related]